Crystallization and preliminary X-ray diffraction analysis of suramin, a highly charged polysulfonated napthylurea, complexed with a myotoxic PLA 2 from Bothrops asper venom

Biochimica et Biophysica Acta - Proteins and Proteomics

Volumn 1703, Issue 1, 2004, Pages 83-85

  Murakami, Mário T ^a   Gava, Lisandra M ^a   Zela, Sandro P ^a   Arruda, Emerson Z ^b   Melo, Paulo A ^b   Gutierrez, José M ^c   Arni, Raghuvir K ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c UNIVERSIDAD DE COSTA RICA   (Costa Rica)

Author keywords

Lys49 PLA 2s; Myotoxicity; Snake venom; Suramin; X ray diffraction

Indexed keywords

NAPHTHALENE DERIVATIVE; PHOSPHOLIPASE A2; SNAKE VENOM; SURAMIN; UREA DERIVATIVE;

ARTICLE; COMPLEX FORMATION; CRYSTAL; CRYSTALLIZATION; DIFFUSION; INFORMATION PROCESSING; PRIORITY JOURNAL; X RAY DIFFRACTION;

ANIMALS; BOTHROPS; CROTALID VENOMS; CRYSTALLOGRAPHY, X-RAY; LYSINE; MOLECULAR STRUCTURE; PHOSPHOLIPASES A; SURAMIN; UREA; X-RAY DIFFRACTION;

BOTHROPS ASPER; SERPENTES;

EID: 9644258969     PISSN: 15709639     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbapap.2004.08.009     Document Type: Article

References (30)

1. M. Hosang Suramin binds to platelet-derived growth factor and inhibits its biological activity J. Cell. Biochem. 29 1985 265 273
2. S.S. Huang, and J.S. Huang Rapid turnover of the platelet-derived growth factor receptor in cis-transformed cells and reversal by suramin: Implications for the mechanism of autocrine transformation J. Biol. Chem. 263 1988 12608 12618
3. D.B. Rifkin, and D. Moscatelli Recent developments in the cell biology of basic fibroblast growth factor J. Cell Biol. 109 1989 1 6
4. S.G. Arbuck, J.M. Sorensen, M.C. Christian, P. Ho, J.M. Pluda, and B.D. Cheson New drugs in non-Hodgkin's lymphoma Ann. Oncol. Suppl. 1 1997 119 128
5. C.E. Hensey, D. Boscoboinik, and A. Azzi Suramin, anti-cancer drug, inhibits protein kinase C and induces differentiation in neuroblastoma cell clone NB2A FEBS Lett. 258 1989 156 158
6. B.D. Cheson, A.M. Levine, D. Mildvan, L.D. Kaplan, P. Wolfe, A. Rios, J.E. Groopman, P. Gill, P.A. Volberding, and B.J. Poiesz Suramin therapy in AIDS and related disorders. Report of the US Suramin Working Group JAMA 258 1987 1347 1351
7. M.A. Eisenberger, L.M. Reyno, D.I. Jodrell, V.J. Sinibaldi, K.H. Tkaczuk, R. Sridhara, E.G. Zuhowski, M.H. Lowitt, S.C. Jacobs, and M.J. Egorin Suramin, an active drug for prostate cancer: Interim observations in a phase I trial J. Natl. Cancer Inst. 85 1993 611 621
8. R. Dreicer, D.C. Smith, R.D. Williams, and W.A. See Phase II trial of suramin in patients with metastatic renal cell carcinoma Invest. New Drugs 17 1999 183 186
9. W.J. Gradishar, G. Soff, J. Liu, A. Cisneros, S. French, A. Rademaker, A.B. Benson, and N. Bouck A pilot trial of suramin in metastatic breast cancer to assess antiangiogenic activity in individual patients Oncology-Basel 58 2000 324 333
10. E.Z. Arruda, N.M.V. Silva, R.A.M. Moraes, and P.A. Melo Effect of suramin on myotoxicity of some crotalid snake venoms. Antimyotoxic effect of suramin Braz. J. Med. Biol. Res. 35 2002 723 726
11. M. Oliveira, W.L.G. Cavalcante, E.Z. Arruda, P.A. Melo, M.D. Silva, and M. Gallaccia Antagonism of myotoxic and paralyzing activities of bothropstoxin-I by suramin Toxicon 42 2003 373 379
12. 2 Enzymes: Structure, Function and Mechanism 1997 Wiley Chichester 321 352
13. J.B. Harris Phospholipases in snake venoms and their effects on nerve and muscle A.L. Harvey Snake Toxins 1991 Pergamon Press New York 91 121
14. 2 enzymes: regulation and physiological role Biochem. Pharmacol. 48 1994 1 10
15. 2 Methods Enzymol. 197 1991 201 215
16. 2: clues towards identification of residues involved in a novel mechanism of membrane damage and in myotoxicity Protein Eng. 11 1998 285 294
17. R.M. Kini, and S. Iwanaga Structure-function relationships of phospholipases: II. Charge density distribution and the myotoxicity of presynaptically neurotoxic phospholipases Toxicon 24 1986 895 905
18. R.M. Kini, and H.J. Evans Role of cationic residues in cytolytic activity: modification of lysine residues in the cardiotoxin from Naja nigricollis venom and correlation between cytolytic and antiplatelet activity Biochemistry-US 28 1989 9209 9216
19. 2 isolated from Bothrops asper and Bothrops godmani snake venoms: effects on enzymatic and pharmacological properties Toxicon 35 1997 241 252
20. 2 in Bothrops snake venoms: effect of chemical modification on the enzymatic and pharmacological properties of bothropstoxins from Bothrops jararacussu Biochimie 82 2000 755 763
21. 2 expresses enhanced membrane-damaging activities and reproduces its in vivo myotoxic effect Biochim. Biophys. Acta 1461 1999 19 26
22. 2 from Agkistrodon piscivorus piscivorus snake venom: synthetic C-terminal peptides from Lys49, but not from Asp49 myotoxins, exert membrane-damaging activities Toxicon 39 2001 1587 1594
23. 2 by sequence analysis and site directed mutagenesis Toxicon 42 2003 869 883
24. M.T. Murakami, and R.K. Arni A structure based model for liposome disruption and the role of catalytic activity in myotoxic phospholipase A2s Toxicon 42 2003 903 913
25. 2 Adv. Inorg. Biochem. 10 1994 139 155
26. Z. Otwinowski, and W. Minor Processing of X-ray diffraction data collected in oscillation mode Methods Enzymol. 276 1997 307 326
27. B.W. Matthews Solvent content of protein crystals J. Mol. Biol. 33 1968 491 497
28. J. Navaza AmoRe: an automated package for molecular replacement Acta Crystallogr. A50 1994 157 163
29. 2 Toxicon 36 1998 1623 1633
30. G.N. Murshudov, A.A. Vagin, and E.J. Dodson Refinement of macromolecular structure by the maximum-likelihood method Acta Crystallogr. D53 1997 240 255